LiverLearning®: 2021 Webinar: To Stop or Not to Stop: The Practice of Finite Nucleos(t)ide Analog Therapy

This one-hour webinar will summarize the data that supports the finite strategy of nucleos(t)ide analog (NA) therapy in patients with chronic hepatitis B. Further discussion on how the presenter practices the strategy. In the second half of the webinar, the presenter will present data that argues against the rationale of a finite NA therapy. The presenter will elaborate on why stopping NA before loss of HBsAg cannot be recommended.

Transcriptional Enhancer Factor Domain Family member 4 Exerts an Oncogenic Role in Hepatocellular Carcinoma by Hippo‐Independent Regulation of Heat Shock Protein 70 Family Members

Mairene Coto‐Llerena, Nadia Tosti, Stephanie Taha‐Mehlitz, Venkatesh Kancherla, Viola Paradiso, John Gallon, Gaia Bianco, Andrea Garofoli, Souvik Ghosh, Fengyuan Tang, Caner Ercan, Gerhard M. Christofori, Matthias S. Matter, Raoul A. Droeser, Mihaela Zavolan, Savas D. Soysal, Markus Flüe, Otto Kollmar, Luigi M. Terracciano, Charlotte K. Y.

Metabolic Profiling of Bile Acids in the Urine of Patients with Alcohol‐Associated Liver Disease

Liqing He, Vatsalya Vatsalya, Xipeng Ma, Jiayang Zhang, Xinmin Yin, Seongho Kim, Wenke Feng, Craig J. McClain, Xiang Zhang – 19 January 2021 – Bile acids (BAs) play important functions in the development of alcohol‐associated liver disease (ALD). In the current study, urine BA concentrations in 38 patients with well‐described alcohol‐associated hepatitis (AH) as characterized by Model for End‐Stage Liver Disease (MELD), 8 patients with alcohol‐use disorder (AUD), and 19 healthy controls (HCs) were analyzed using liquid chromatography–mass spectrometry.

SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH

Yi Luo, Samir Wadhawan, Alex Greenfield, Benjamin E. Decato, Abdul M. Oseini, Rebecca Collen, Diane E. Shevell, John Thompson, Gabor Jarai, Edgar D. Charles, Arun J. Sanyal – 19 January 2021 – Nonalcoholic steatohepatitis (NASH) is a major cause of liver‐related morbidity and mortality worldwide. Liver fibrosis stage, a key component of NASH, has been linked to the risk of mortality and liver‐related clinical outcomes.

Subscribe to